PS5 - Menopause: the Intersection of Metabolism & Hormones

Saturday, November 29, 2025

14:30 - 15:30 Toronto

Location: Constitution Hall

Speaker(s)

MC

Marie K. Christakis, MD, FRCSC, MPH, NCMP (she/her/hers)

Clinical Lead, Weston & O’Born Centre for Mature Women’s Health Assistant Professor
University of Toronto, Sinai Health
University of Toronto
Toronto, Ontario, Canada

Disclosure(s): I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Moderator(s)

Sonja M. Reichert, MD, MSc, FCFP, ABOM Diplomat, Co-Chair: Clinical Care and Education Stream (she/her/hers)

Associate Professor, MD
Western University
Western University
London, Ontario, Canada

Disclosure(s): Abbott: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); American Diabetes Association: Independent Contractor (Terminated, September 1, 2025); Bausch: Advisory Board (Terminated, November 1, 2024); Bayer: Advisory Board (Terminated, June 9, 2025); Center for Effective Practise: Employment (Terminated, January 1, 2025); CPD Network Association: Speaker/Honoraria (Terminated, September 23, 2025); Diabetes Canada: Committee/Planning Member (Ongoing); Eisai: Advisory Board (Terminated, November 20, 2024); Eli Lilly: Advisory Board (Ongoing), Grant/Research Support (Ongoing); Embecta: Advisory Board (Terminated, November 21, 2024); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novo Nordisk: Advisory Board (Terminated, March 1, 2025), Committee/Planning Member (Terminated, March 1, 2025), Grant/Research Support (Terminated, March 1, 2025), Speaker/Honoraria (Terminated, March 1, 2025); Sanofi: Speaker/Honoraria (Terminated, June 4, 2025); Western University: Employment (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Disclosure(s):

Marie K. Christakis, MD, FRCSC, MPH, NCMP: I do not have a relationship with a for-profit and/or a not-for-profit organization to disclose

Sonja M. Reichert, MD, MSc, FCFP, ABOM Diplomat, Co-Chair: Clinical Care and Education Stream: Abbott: Other Research Support (includes receipt of drugs, supplies, equipment or other in-kind support) (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing), Speaker/Honoraria (Ongoing); American Diabetes Association: Independent Contractor (Terminated, September 1, 2025); Bausch: Advisory Board (Terminated, November 1, 2024); Bayer: Advisory Board (Terminated, June 9, 2025); Center for Effective Practise: Employment (Terminated, January 1, 2025); CPD Network Association: Speaker/Honoraria (Terminated, September 23, 2025); Diabetes Canada: Committee/Planning Member (Ongoing); Eisai: Advisory Board (Terminated, November 20, 2024); Eli Lilly: Advisory Board (Ongoing), Grant/Research Support (Ongoing); Embecta: Advisory Board (Terminated, November 21, 2024); Novartis: Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing); Novo Nordisk: Advisory Board (Terminated, March 1, 2025), Committee/Planning Member (Terminated, March 1, 2025), Grant/Research Support (Terminated, March 1, 2025), Speaker/Honoraria (Terminated, March 1, 2025); Sanofi: Speaker/Honoraria (Terminated, June 4, 2025); Western University: Employment (Ongoing), Research Grant (includes principal investigator, collaborator or consultant and pending grants as well as grants already received) (Ongoing)

Learning Objectives: This sessions will:
1. Analyze the pathophysiological changes associated with menopause and their contributions to changes in glucose metabolism, insulin sensitivity, and adiposity.
2. Evaluate the current evidence on the relationship between menopause, type 2 diabetes risk, and metabolic syndrome.
3. Assess the risks and benefits of hormone therapy and other interventions in postmenopausal individuals with or at risk for diabetes.